Drug Availability Update
Further to DrugAlert Vol 472, HPS Pharmacies wish to give notice that Merck Sharp & Dohme (Australia) are continuing to experience a supply interruption for OncoTICE® vials as follows:
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) 5 hundred million CFU
This supply interruption is due to an unexpected increase in demand. Normal supplies are expected to resume in early January 2020. While stocks are limited, HPS Pharmacies has been able to secure a very limited supply from the manufacturer. As this supply is insufficient to meet current demands, therapeutic alternatives should be considered if appropriate.
An internationally registered brand of BCG vials is approved for supply under Section 19A of the Therapeutic Goods Act 1989. Unfortunately, this product is now also unavailable with no estimated date of return.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Merck Sharp & Dohme (Australia) on (02) 8988 8000or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates